Fast Five Quiz: Molecular and Biomarker Analysis in Non–Small Cell Lung Cancer (NSCLC)

Daniel S. Schwartz, MD; Maurie Markman, MD

August 30, 2022

In 2020, there were 2.21 million new cases of lung cancer and 1.8 million deaths from lung cancer worldwide. Approximately 85% of all lung cancers fall under the non–small cell lung cancer (NSCLC) category. Advances in targeted therapies have increased the importance of identifying oncogenic drivers that can act both as therapeutic targets and predictive biomarkers.

How much do you know about molecular and biomarker analysis in NSCLC? Test your knowledge with this quick quiz.

1 2 3 4 5 6

Next Section

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Daniel S. Schwartz, Maurie Markman. Fast Five Quiz: Molecular and Biomarker Analysis in Non–Small Cell Lung Cancer (NSCLC) - Medscape - Aug 30, 2022.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.